Recent Quotes (30 days)

You have no recent quotes
chg | %

Gentium Srl (ADR)  

(Public, OTCMKTS:GENTY)   Watch this stock  
Apr 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 7.26 - 59.25
Open     -
Vol / Avg. 0.00/6,528.00
Mkt cap 872.64M
P/E 108.60
Div/yield     -
EPS 0.52
Shares     -
Beta 1.58
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 22.92% 2.67%
Operating margin 24.15% 2.45%
EBITD margin - 7.47%
Return on average assets 29.28% 2.76%
Return on average equity 40.91% 4.10%
Employees 77 -
CDP Score - -


Piazza XX Settembre, 2
+39-31-5373200 (Phone)
+39-031-385241 (Fax)

Website links


Gentium Srl is an Italy-based biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company’s development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The main shareholder of the Company is Jazz Pharmaceuticals PLC.

Officers and directors

Khalid Islam Ph.D. Chairman of the Board, Chief Executive Officer, Interim Scientific Director
Age: 61
Salvatore Calabrese Chief Financial Officer, Chief Operating Officer
Age: 44
Carin Heringa Senior Vice President, Scientific Director
Age: 52
Marco Maria Brughera Director
Age: 60
Laura Ferro Ph.D. Director
Age: 62
Gigliola Bertoglio CPA Independent Director
Age: 79
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 63
Elmar J. Schnee Independent Director
Age: 57